Lund, Sweden, 17:00 PM CET, 12 February 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries announces a change in its management team. Patrick O’Donnell will leave BONESUPPORT and his role as General Manager & Executive Vice President Commercial Operations North America, effective as of today. As a consequence of this change the Company’s US organization will during an interim period report directly to CEO. The replacement to the position GM & EVP North America will be announced at a later stage. “I would like to thank Patrick for his time within BONESUPPORT and his important contribution to establishing an independent commercial platform in the USA” says CEO Emil Billbäck.
BONESUPPORT™ (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio–ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The Company is conducting several clinical studies to further demonstrate the clinical and health economic benefits that its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2021. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
+46 (0) 708 76 87 87